Dr. Anchalee Avihingsanon, HIV-NAT, Thai Red Cross AIDS and Infectious Diseases Research Collaboration, Thailand
Dr. Anchalee Avihingsanon, MD, PhD 🩺🔬 is a distinguished infectious disease specialist with over 20 years of expertise in HIV/AIDS, tuberculosis, and viral hepatitis research. She leads the HIV-NAT clinical research program at the Thai Red Cross AIDS and Infectious Disease Research Centre in Bangkok 🇹🇭 and serves as Clinical Research Site Leader for ACTG. Dr. Avihingsanon actively shapes national health policies in Thailand and contributes to WHO guideline development 🌏. Her international research spans clinical trials addressing HIV, TB, and emerging infections. She has earned numerous awards for her impactful work in resource-limited settings.
Publication Profile
Orcid
Education
Dr. Anchalee Avihingsanon completed her medical degree (MD) at Khon Kaen University, Thailand, from 1986 to 1992. She then specialized in Internal Medicine at Chulalongkorn University, Bangkok, during 1994-1996, followed by a focus on Infectious Disease from 1998 to 1999 at the same institution. Dr. Avihingsanon advanced her expertise as a research fellow in Infectious Diseases at Beth Israel Deaconess Medical Center in Boston, USA, from 2000 to 2002. She earned her PhD in HIV and Coinfection at Amsterdam University, The Netherlands, between 2011 and 2013.
Experience
Dr. Anchalee Avihingsanon has been actively involved in numerous professional roles since 1999. She currently serves as the ACTG Regional Representative for Asia and is a key member of several WHO advisory groups on HIV, viral hepatitis, and STIs. She is also an infectious disease expert on Bangkok’s Essential Medicine Committee and contributes to national efforts on AIDS, TB, and hepatitis. Dr. Avihingsanon participates in multiple research and guideline committees, including the Thai Ministry of Public Health and international scientific groups. She holds memberships in prestigious organizations like the International AIDS Society and the Royal College of Physicians.
Awards
Dr. Anchalee Avihingsanon has received numerous honors throughout her career. In 2016, she successfully passed the US-FDA inspection for key studies. She was awarded the Australia-APEC Women in Research Fellowship in 2015 and received the prestigious NUFFIC PhD grant from the Netherlands Embassy during 2011-2013. Dr. Avihingsanon earned scholarships to attend global workshops and conferences, including the European AIDS Conference and International AIDS Society from 2007 to 2022. Early in her career, she was recognized as Best Doctor at Samutsakorn Hospital in 1998 and served as chief resident at King Chulalongkorn Memorial Hospital in 1997.
Research Focus
Dr. Anchalee Avihingsanon is a distinguished researcher specializing in HIV and Hepatitis C co-infections, with a strong focus on antiretroviral therapy optimization, pharmacokinetics, and treatment outcomes. Her work includes evaluating minimal monitoring HCV treatments, assessing drug interactions in people living with HIV, and improving health-related quality of life for patients. She also investigates malnutrition, sarcopenia risks in elderly HIV patients, and liver fibrosis progression using advanced diagnostics. Anchalee’s contributions significantly impact infectious disease management, particularly in Asian populations, aiming to enhance therapy safety, efficacy, and accessibility.
Publication Top Notes
Impact of a minimal monitoring HCV treatment approach on Health-Related Quality of Life
The population pharmacokinetics of dolutegravir co‐administered with rifampicin in Thai people living with HIV: Assessment of alternative dosing regimens
Performance of Elecsys® HCV Duo Immunoassay for Diagnosis and Assessment of Treatment Response in HCV Patients with or without HIV Infection
The Risk of Malnutrition and Sarcopenia in Elderly People Living with HIV during the COVID-19 Pandemic
Pharmacokinetics of Sofosbuvir/Velpatasvir and efficacy of an alternate‐day treatment in hemodialysis patients with chronic hepatitis C infection
Efficacy and safety of switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed Asian adults living with HIV: A pooled analysis from three international phase III randomized trials
The 25th Bangkok International Symposium on HIV Medicine
Dose optimization with population pharmacokinetics of ritonavir-boosted lopinavir for Thai people living with HIV with and without active tuberculosis
Conference Proceedings from the Virtual 24th Bangkok International Symposium on HIV Medicine
Third‐line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource‐limited settings: ACTG A5288 strategy trial